CN115745941A - 新型阳离子脂质化合物 - Google Patents
新型阳离子脂质化合物 Download PDFInfo
- Publication number
- CN115745941A CN115745941A CN202111030769.4A CN202111030769A CN115745941A CN 115745941 A CN115745941 A CN 115745941A CN 202111030769 A CN202111030769 A CN 202111030769A CN 115745941 A CN115745941 A CN 115745941A
- Authority
- CN
- China
- Prior art keywords
- composition
- compound
- lipid
- therapeutic
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 cationic lipid compounds Chemical class 0.000 title claims abstract description 16
- 150000002632 lipids Chemical class 0.000 claims abstract description 70
- 239000000203 mixture Substances 0.000 claims abstract description 58
- 150000001875 compounds Chemical class 0.000 claims abstract description 53
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 23
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 20
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 18
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 14
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 14
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 14
- 230000007935 neutral effect Effects 0.000 claims abstract description 13
- 150000003431 steroids Chemical class 0.000 claims abstract description 13
- 229920000642 polymer Polymers 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 150000001204 N-oxides Chemical class 0.000 claims abstract description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 9
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 8
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 4
- 241000720974 Protium Species 0.000 claims description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims description 2
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 claims description 2
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 claims description 2
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims description 2
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 claims description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 2
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims description 2
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims description 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 claims description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- XYNPYHXGMWJBLV-VXPJTDKGSA-N Tomatidine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@@]11CC[C@H](C)CN1 XYNPYHXGMWJBLV-VXPJTDKGSA-N 0.000 claims description 2
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 claims description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 2
- 229940087168 alpha tocopherol Drugs 0.000 claims description 2
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 2
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 claims description 2
- 235000004420 brassicasterol Nutrition 0.000 claims description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 2
- 235000000431 campesterol Nutrition 0.000 claims description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 2
- 229960004956 glycerylphosphorylcholine Drugs 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- PWRIIDWSQYQFQD-UHFFFAOYSA-N sisunine Natural products CC1CCC2(NC1)OC3CC4C5CCC6CC(CCC6(C)C5CCC4(C)C3C2C)OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OC(CO)C(O)C(O)C9OC%10OC(CO)C(O)C(O)C%10O)C8O)C(O)C7O PWRIIDWSQYQFQD-UHFFFAOYSA-N 0.000 claims description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 2
- 235000015500 sitosterol Nutrition 0.000 claims description 2
- 229950005143 sitosterol Drugs 0.000 claims description 2
- 239000004055 small Interfering RNA Substances 0.000 claims description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 2
- 235000016831 stigmasterol Nutrition 0.000 claims description 2
- 229940032091 stigmasterol Drugs 0.000 claims description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 2
- 229960000984 tocofersolan Drugs 0.000 claims description 2
- XYNPYHXGMWJBLV-OFMODGJOSA-N tomatidine Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@]6(O[C@H]5C4)NC[C@@H](C)CC6)CC3)CC2)CC1 XYNPYHXGMWJBLV-OFMODGJOSA-N 0.000 claims description 2
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 2
- 229940096998 ursolic acid Drugs 0.000 claims description 2
- 239000002076 α-tocopherol Substances 0.000 claims description 2
- 235000004835 α-tocopherol Nutrition 0.000 claims description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 claims 1
- QYIXCDOBOSTCEI-NWKZBHTNSA-N coprostanol Chemical compound C([C@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-NWKZBHTNSA-N 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 108020005544 Antisense RNA Proteins 0.000 abstract 1
- 239000003184 complementary RNA Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 28
- 239000000126 substance Substances 0.000 description 27
- 238000003786 synthesis reaction Methods 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 239000000443 aerosol Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 108060001084 Luciferase Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 125000002091 cationic group Chemical group 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 3
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 3
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229940126657 Compound 17 Drugs 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229940126543 compound 14 Drugs 0.000 description 3
- 229940126086 compound 21 Drugs 0.000 description 3
- 229940125846 compound 25 Drugs 0.000 description 3
- 229940127204 compound 29 Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229940068917 polyethylene glycols Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940126586 small molecule drug Drugs 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 1
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 1
- VTRBOZNMGVDGHY-UHFFFAOYSA-N 6-(4-methylanilino)naphthalene-2-sulfonic acid Chemical compound C1=CC(C)=CC=C1NC1=CC=C(C=C(C=C2)S(O)(=O)=O)C2=C1 VTRBOZNMGVDGHY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000254064 Photinus pyralis Species 0.000 description 1
- 229930185560 Pseudouridine Natural products 0.000 description 1
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 238000003120 Steady-Glo Luciferase Assay System Methods 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GTTSNKDQDACYLV-UHFFFAOYSA-N Trihydroxybutane Chemical compound CCCC(O)(O)O GTTSNKDQDACYLV-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 239000008243 triphasic system Substances 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/12—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
发明涉及脂质化合物,其可以单独使用,或者与其他脂质组分例如中性脂质、带点脂质、类固醇和/或它们的类似物、和/或聚合物缀合的脂质联合使用,以形成用于递送治疗剂和/或预防剂的脂质纳米颗粒。在一些实例中,将脂质纳米颗粒用于递送核酸,例如信使RNA和/或反义RNA。还提供了使用这类脂质纳米颗粒来治疗和/或预防各种疾病的方法。在一个实施方案中,提供了具有下式(I)结构的化合物:或其盐或其异构体或其N‑氧化物,其中R1、R2和R3如文中所定义。还提供了包括一种或多种前述结构式(I)的化合物和治疗剂和/或预防剂的药物组合物。在一些实施方案中,药物组合物还包括选自中性脂质、带电脂质、类固醇和聚合物缀合的脂质的一种或多种组分。这类组合物对于形成用于递送治疗剂和/或预防剂的脂质纳米颗粒是有用的。在其他实施方案中,本发明提供了向有需要的受试者施用治疗剂和/或预防剂的方法,所述方法包括制备包含结构式(I)的化合物的脂质纳米颗粒物和治疗剂和/或预防剂的药物组合,并向受试者递送组合物。
Description
技术领域
本发明提供新型阳离子脂质,其可用于与其他脂质组分(如中性脂质、类固醇和聚合物缀合的脂质)结合,以便形成一种核酸mRNA脂质纳米粒子组合物将一种或多种治疗剂和/ 或预防剂递送至哺乳动物细胞或器官和/或在哺乳动物细胞或器官中产生多肽的方法。除新型脂质外,本发明的脂质纳米粒子组合物还可以包括成特定比例的一种或多种阳离子性和/或可离子化氨基脂质、包括多不饱和脂质在内的中性脂质、聚合物缀合的脂质、类固醇、和/或治疗剂和/或预防剂。
背景技术
生物活性物质如小分子药物、蛋白质和核酸的有效靶向递送提出了一个持久的医学难题。确切地说,将核酸递送至细胞因这些物种的相对不稳定性和低细胞渗透性而变得困难。因此,需要开发有助于将治疗剂和/或预防剂如核酸递送至细胞的方法和组合物。
经研究证明,利用含脂质的纳米颗粒组合物、脂质体和脂质体复合物作运输媒介,可有效地将生物活性物质如小分子药物、蛋白质和核酸运送至细胞和/或细胞内隔室中。这些组合物一般包含一种或多种"阳离子性"脂质,包括多不饱和脂质在内的中性脂质(如磷脂)、结构性脂质(如类固醇)和/或含聚乙二醇的脂质(聚合物缀合的脂质)。阳离子脂质包括如可容易地质子化的含胺脂质。
然而,在治疗环境中使用寡核苷酸目前面临着两个问题。第一,游离的RNA易于在血浆中被核酸酶消化。第二,游离RNA进入存在相关翻译机制的细胞内隔室的能力受限。由阳离子脂质与其他脂质组分(如中性脂质、胆固醇、PEG、PEG化的脂质和寡核苷酸)形成的脂质纳米颗粒已用于阻止RNA在血浆中的降解并促进寡核苷酸的细胞摄取。
仍然有必要改进的用于递送寡核苷酸的阳离子脂质和脂质纳米颗粒。改进后的脂质纳米颗粒会提供优化的药物递送,保护核酸不在血清中被降解和清除,其适于全身或局部递送,并且提供核酸的细胞内递送。另外,这些优选的脂质-核酸颗粒应当是耐受良好的,并且提供足够的治疗指数,使得在有效剂量的核酸下的患者治疗不会对患者产生不可接受的毒性和/或风险。本发明提供这些优点和相关的优点。
发明内容
本发明提供以下新型化合物和涉及这些化合物的方法:
第一方面,本发明涉及以下结构式(I)的化合物:
或其N-氧化物,或其盐或异构体。
其中结构式“I”中的R1、R2和R3均为独立的2个“氢”同位素(包括同位素“氕”和“氘”)的组合,具体表现R1为“HH”、“HD”和“DD”的组合;R2和R3“HHH”、“HHD”、“HDD”和“DDD”的组合;
R1、R2和R3均有独立性,但R1、R2和R3中的同位素“氕”和“氘”不能同时为“H”,即至少含有一个“D”的组合,具体组合情况分5种情况,包括含1个“D”的组合、含2个“D”的组合、含3个“D”的组合、含4个“D”的组合和含5个“D”的组合。
在各个不同的实施方案中,所述化合物具有以下表1中所示的结构之一
表1代表性化合物
在一些实施方案中,提供了包含结构式(I)的化合物中的任一种或多种和治疗剂和/或预防剂的组合物。
在一些实施方案中,提供了包含结构(I)的化合物中的任一种或多种和治疗剂和/或预防剂的组合物。在一些实施方案中,所述组合物包含结构(I)的化合物中的任一种和治疗剂和/或预防剂以及一种或多种选自中性脂质、类固醇和聚合物缀合的脂质的赋形剂。其他药物可接受的赋形剂和/或载体也包括在组合物的各种实施方案内。
在一些实施方案中,中性脂质选自1,2-二硬脂酰基-sn-甘油-3-磷酸胆碱(DSPC)、1,2- 二棕榈酰基-sn-甘油-3-磷酸胆碱(DPPC)、1,2-二肉豆寇基-sn-甘油-磷酸胆碱(DMPC)、1, 2-二油酰基-sn-甘油-3-磷酸胆碱(DOPC)、1-棕榈酰基-2-油酰基-sn-甘油-3-磷酸胆碱(POPC)、 1,2-二油酰基-sn-甘油-3-磷酸乙醇胺(DOPE)、鞘磷脂(SM)中的一种或多种。在一些实施方案中,优选中性脂质为1,2-二硬脂酰基-sn-甘油-3-磷酸胆碱(DSPC)。
在一些实施方案中,类固醇选自胆固醇、类固醇、谷固醇、麦角固醇、菜油固醇、豆固醇、菜籽固醇、番茄碱、熊果酸、α-生育酚中的一种或多种。在一些实施方案中,优选类固醇为胆固醇。
在一些实施方案中,聚乙二醇化脂质为1,2-二肉豆蔻酰基-sn-甘油甲氧基聚乙二醇 (PEG-DMG)
在一些实施方案中,所述组合物比例以下范围:约10~60mol%所述化合物、约0~30mol%中性脂质、约10~55mol%类固醇和约0~10mol%聚合物缀合的脂质。
在一些前述组合物的实施方案中,治疗剂和/或预防剂包括核酸。其中核酸为RNA,其选自以下组成:siRNA、aiRNA、miRNA、dsRNA、shRNA、mRNA以及其混合物。在一些实施方案中,所述RNA选自mRNA。
在其他不同的实施方案中,本发明涉及向有需要的受试者使用治疗剂和/或预防剂的方法,该方法包括制备或提供上述组合物中的任一种并向受试者使用该组合物。
出于使用的目的,本发明的化合物可以以原料药使用,或者可以配制为药物组合物(通常是脂质纳米颗粒与治疗剂和/或预防剂结合的形式)。本发明的药物组合物包含结构(I)的化合物和一种或多种药物可接受的载体、稀释剂或赋形剂。结构(I)的化合物以有效形成脂质纳米颗粒并递送治疗剂和/或预防剂。本领域技术人员可以容易地确定适当的浓度和剂量。
本发明组合物的使用可以通过任何用于类似效用的试剂的可接受使用方式来进行。本发明的药物组合物可以配制成固体、半固体、液体或气体形式的制剂,例如片剂、胶囊、粉末、颗粒、软膏、溶液、混悬液、栓剂、注射剂、吸入剂、凝胶、微球和气溶胶。使用这类药物组合物的典型途径包括,但不限于口服、局部、经皮、吸入、胃肠外、舌下、口含、直肠、阴道和鼻内途径。本文使用的术语胃肠外包括皮下注射,静脉内、肌内、皮内、胸骨内注射或输注技术。配制本发明的药物组合物是为了使其中的活性成分在受试者体内生物可利用。待向对象或患者使用的组合物形式可以是一个或多个剂型,其中,片剂可以是单剂量单位,而本发明气溶胶形式的化合物的容器可以容纳多个剂量单位。制备这些剂型的现行的方法是己知的,或者对于本领域技术人员是显而易见的。在任何情况下,待使用的组合物将会含有治疗有效量的本发明化合物或其药物可接受的盐,以便根据本发明的教导治疗相关的疾病或病况。
本发明的药物组合物可以是固体或液体的形式。一方面,载体可以是颗粒,使得组合物是片剂或粉末形式。载体还可以是液体,此时组合物是口服糖浆或可注射液体或气溶胶,所述气溶胶适用于吸入使用。
当要用于口服使用时,药物组合物优选为固体或液体形式,其中本文认为固体或液体的形式包括半固体、半液体、混悬液和凝胶。
作为用于口服使用的固体组合物,药物组合物可以配制成粉末、颗粒、片剂、丸剂、胶囊、咀嚼胶、薄片等形式。这类固体组合物通常将含有一种或多种惰性稀释剂或可食用载体。另外,可以存在以下的一种或多种:粘合剂,如明胶、纤维素等;赋形剂,如乳糖等;崩解剂,如海藻酸等;润滑剂,如硬脂酸镁等;助流剂,如硅胶等;甜味剂,如蔗糖或糖精;调味剂,如薄荷等;以及着色剂。
当药物组合物是胶囊形式时,其可以含有上述类型材料之外的液体载体,如聚乙二醇或油。
药物组合物可以是液体的形式,如糖浆、溶液、乳液或混悬液。作为两种实例,液体可以用于口服使用或用于注射递送。当意图用于口服使用时,优选的组合物含有除本发明化合物之外的甜味剂、防腐剂、染色/着色剂和增味剂中的一种或多种。在通过注射使用的组合物中,可以包括表面活性剂、防腐剂、润湿剂、分散剂、混悬剂、缓冲剂、稳定剂和等渗剂中的一种或多种。
本发明的液体药物组合物,不论其为溶液、混悬液还是其他类似的形式,可以包括以下辅料中的一种或多种:无菌稀释剂,如注射用水、盐水溶液、优选生理盐水、林格氏溶液、等渗氯化钠;不挥发性油类,如可用作溶剂或混悬介质的合成的单甘酯或双甘酯,聚乙二醇、甘油、丙二醇或其他溶剂;抗菌剂,如尼泊金甲酯等;抗氧化剂,如抗坏血酸或亚硫酸氢钠;螯合剂,如乙二胺四乙酸;缓冲剂,如乙酸盐、柠檬酸盐或磷酸盐;以及用于调节张力的试剂,如氯化钠或葡萄糖;用作冷冻保护剂的试剂,如蔗糖或海藻糖。胃肠外制剂可以封装在玻璃或塑料制作的安瓿、一次性注射器或多剂量瓶中。生理盐水是优选的佐剂。可注射的药物组合物优选为无菌的。
本发明的药物组合物可以用于局部使用,在这种情况下,载体可以适当地包含溶液基质、乳液基质、软膏基质或凝胶基质。所述基质可以包含以下的一种或多种:矿脂、羊毛脂、聚乙二醇、蜂蜡、矿物油、诸如水和醇的稀释剂、以及乳化剂和稳定剂。增稠剂可以存在于用于局部使用的药物组合物中。如果意图用于经皮使用,组合物可以包括经皮贴片或离子电渗装置。
本发明的药物组合物可以包括修饰固体或液体剂型的物理形式的各种材料。组合物可以包括形成活性成分周围的包衣壳的材料。形成包衣壳的材料通常是惰性的,并且可以为糖、虫胶和其他肠溶包衣试剂。或者活性成分可以封装在明胶胶囊中。
本发明固体或液体形式的药物组合物可以包括与本发明化合物结合,有助于所述化合物递送载体。这种载体包括单克隆或多克隆抗体或蛋白质。
本发明的药物组合物可以由可作为气溶胶使用的制剂组成。术语气溶胶表示包含胶体性质的系统和由加压包装组成的系统。可以通过液化气或压缩气来递送,或者通过分散活性成分的适合的泵系统来递送。本发明化合物的气溶胶可以以单相、双相系统或三相系统来递送,以便递送活性成分。气溶胶的递送包括必要的容器、活化剂、阀、子容器等,其在一起可以形成给药装置。本领域技术人员不需额外实验即可确定优选的气溶胶。
本发明的药物组合物可以通过制药领域熟知的方法来制备。通过注射使用的药物组合物可以将本发明的脂质纳米颗粒与无菌的蒸馏水或其他载体结合成溶液来制备。可以加入表面活性剂以促进形成均匀的溶液或混悬液。表面活性剂是通过本发明化合物非共价地相互作用,从而促进所述化合物在水溶性介质中溶解或均匀混悬。
本发明的组合物或其药物可接受的盐以治疗有效量使用,所述量将会根据多种因素变化,包括使用的具体治疗剂的活性;治疗剂的代谢稳定性和作用时长;受试者的年龄、体重、一般健康状况、性别和饮食;使用的方式和时间;排泄速率;药物组合;具体病例的严重性等。
本发明的组合物也可以在使用一种或多种其他治疗剂的同时、之前或之后使用。这类治疗组合包括单独使用本发明组合物的制剂以及使用本发明组合物和其它一种或多种活性成分的组合。例如,本发明组合物和其他活性成分可以以单一口服剂量制剂(如片剂或胶囊)一起向受试者使用,或者各个活性成分以不同的口服剂量制剂使用。当使用不同的剂量制剂时,本发明化合物和一种或多种另外的活性成分可以在同一时间使用,或者在相互交错的时间依次使用;应理解组合治疗包括所有的这些给药方案。
上述新型氘代阳离子脂质化合物的结构修饰和设计,实现了更有优势的理化性质,包括更合适的pKa和更好的化学稳定性,用于mRNA纳米脂质体组合物,可实现对离子类核酸药物更有效结合并递送,同时其化学结构更稳定,便于合成和有利开发为药用辅料。
上述化合物和组合物的制备方法在下文描述,和/或在本领域已知。
本领域的技术人员将会认识到,在本文描述的方法中,中间化合物的官能团可能需要通过适合的保护基保护。这类官能团包括羟基、氨基和羧酸。用于羟基的适合的保护基包括三烷基甲硅烷基或二芳基烷基甲硅烷基、四氢呋喃基、苄基等。用于氨基的适合的保护基包括叔丁氧基羰基、苄氧基羰基等。用于羧酸的适合的保护基包括羟基、芳基或芳烃基酯。保护基可以根据标准技术添加或去除,所述标准技术是本领域技术人员已知的和本文中描述的。
本领域技术人员还将认识到,虽然本发明化合物的这类经保护的衍生物可以不由此具有药物活性,但其可以对哺乳动物施用并且之后在体内代谢形成具有药理活性的本发明化合物。这类衍生物因此可以被描述为“前药”。所以本发明化合物的前药包括在本发明的范围内。
此外,所有以游离碱或游离酸形式存在的本发明化合物可以根据本领域技术人员已知的方法用适当的无机或有机的碱或酸处理来转化为其药物可接受的盐。本发明化合物的盐可以通过标准技术转化为其游离碱或酸形成。
提供了以下实施例,其目的在于举例展示,并非限定。
以下实施例,除非另外指出,否则使用的所有溶剂和试剂都是商购得到并且以原样使用。
以下描述的程序可用于合成表1中的化合物I。
本文采用了以下缩写:
具体实施方式
实施例1:
代表性路线
化合物3的合成
1)化合物B的合成
化学式:C37H66O
分子量:526.93
向化合物A(6.0g,11.4mmol)和PCC(7.39g,34.2mmol)的DCM混合液中加入碳酸钠(1.0g,5.66mmol),氮气保护。在室温下反应3h,中控至反应至终点。反应结束垫如硅藻土进行过滤,滤饼用DCM淋洗。合并有机相,涤,硫酸镁干燥后,过滤浓缩,所得残余物通过硅胶柱(0~15%乙酸乙酯/正己烷)纯化。得化合物B(4.2g,收率70%)。
2)化合物3-01的合成
化学式:C41H72D2O3
分子量:617.05
将化合物B(4.2g,8.2mmol)、1,2,4-4,4-d2-丁三醇(3.4g,32.0mmol)和PPTS(200.0mg, 0.8mmol)加入到盛有甲苯(60mL)反应瓶中,开启搅拌,在氮气保护下加热回流反应过夜,同时利用分水器进行分水至原料反应完全。将体系降至室温,加入50mL甲苯进行稀释,依次用5%的碳酸钠水溶液和水进行洗涤,经无水硫酸镁干燥后,通过层析柱纯化得3-01(3.0 克,59%收率)。
3)化合物3-02的合成
化学式:C42H74D2O5S
分子量:695.14
将化合物3-01(3.0g,4.9mmol)和TEA(1.58g,15.6mmol)加入到装有20mL二氯甲烷的反应瓶中。氮气保护后,降至-15℃。将MsCl(1.11g,9.7mmol)的二氯甲烷溶液(约32mL)逐滴加入到上述体系中,约20分钟加料完毕。保温反应2.5小时,中控至原料反应完全。向体系中加入50mL的二氯甲烷进行稀释,依次用饱和碳酸氢钠和饱和食盐水洗涤,有机相经无水硫酸镁干燥,过滤,减压浓缩移除溶剂。粗品通过柱层析进行过柱纯化,得3-02(3.05g,91%收率)
4)化合物3的合成
化学式:C43H77D2NO2
分子量:644.12
将化合物3-02(3.0g,4.35mmol)加入到盛有25mL的异丙醇的反应瓶中,开启搅拌并进行氮气保护。将120mL2.0M的二甲胺的甲醇溶液逐渐加入上述体系中,保温反应72小时,至原料反应完全。将体系减压浓缩移除溶剂,所得粗品经通过硅胶柱(0~100%(1%NH4OH、20%MeOH于二氯甲烷中的混合物)二氯甲烷)纯化,得化合物3(2.49g,收率89%)。
C43H77D2NO2,Ms m/z:[M+H+]644.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82~2.78(d,4H),2.26-2.15(m,14H,),1.51-1.50(m,6H),1.33-1.26(m,36H),0.88(t, 6H)。
实施例2:
化合物1的合成
化学式:C43H78DNO2
分子量:643.12
化合物1可根据实施例1描述的代表性路线合成。
C43H78DNO2,Ms m/z:[M+H+]643.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m, 3H),2.82~2.78(d,4H),2.43(t,1H),2.26-2.15(m,14H),1.51-1.50(m,6H),1.33-1.26(m,36H), 0.88(t,6H).
实施例3:
化合物2的合成
分子量:643.12
化合物2可根据实施例1描述的代表性路线合成。
C43H78DNO2,Ms m/z:[M+H+]643.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m, 3H),2.82-2.78(d,4H),2.43-2.41(t,2H),2.26-2.15(m,13H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H).
实施例4:
化合物4的合成
分子量:644.14
化合物4可根据实施例1描述的代表性路线合成。
C43H77D2NO2,Ms m/z:[M+H+]644.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.43-2.41(t,2H),2.26-2.15(m,12H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H).
实施例5:
化合物5的合成
化合物5可根据实施例1描述的代表性路线合成。
C43H77D2NO2,Ms m/z:[M+H+]644.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.42(t,1H),2.26-2.15(m,13H),1.51-1.50(m,6H),1.33-1.26(m,36H), 0.88(t,6H).
实施例6:
化合物6的合成
化学式:C43H77D2NO2
分子量:644.14
化合物6可根据实施例1描述的代表性路线合成。
C43H77D2NO2,Ms m/z:[M+H+]644.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.43-2.41(t,2H),2.26-2.15(m,12H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H).
实施例7:
化合物7的合成
分子量:645.14
化合物7可根据实施例1描述的代表性路线合成。
C43H76D3NO2,Ms m/z:[M+H+]645.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.26-2.14(m,13H),1.51-1.50(m,6H),1.33-1.26(m,36H),0.88(t, 6H).
实施例8:
化合物8的合成
化合物8可根据实施例1描述的代表性路线合成。
C43H76D3NO2,Ms m/z:[M+H+]645.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.42(t,1H),2.26-2.15(m,12H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H).
实施例9:
化合物9的合成
化合物9可根据实施例1描述的代表性路线合成。
C43H76D3NO2,Ms m/z:[M+H+]645.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.43(t,1H),2.26-2.15(m,12H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H).
实施例10:
化合物10的合成
化学式:C43H76D3NO2
分子量:645.14
化合物10可根据实施例1描述的代表性路线合成。
C43H76D3NO2,Ms m/z:[M+H+]645.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.41(t,2H),2.26-2.15(m,11H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H)。
实施例11:
化合物11的合成
分子量:645.14
化合物11可根据实施例1描述的代表性路线合成。
C43H76D3NO2,Ms m/z:[M+H+]645.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.41(t,2H),2.26-2.15(m,11H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H).
实施例12:
化合物12的合成
化合物12可根据实施例1描述的代表性路线合成。
C43H75D4NO2,Ms m/z:[M+H+]646.7;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.26-2.15(m,12H),1.51-1.50(m,6H),1.33-1.26(m,36H),0.88(t, 6H).
实施例13:
化合物13的合成
化合物13可根据实施例1描述的代表性路线合成。
C43H75D4NO2,Ms m/z:[M+H+]646.7;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.26-2.15(m,12H),1.51-1.50(m,6H),1.33-1.26(m,36H),0.88(t, 6H)。
实施例14:
化合物14的合成
化学式:C43H75D4NO2
分子量:646.15
化合物14可根据实施例1描述的代表性路线合成。
C43H75D4NO2,Ms m/z:[M+H+]646.7;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.41(t,2H),2.26-2.14(m,10H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H)。
实施例15:
化合物15的合成
化合物14可根据实施例1描述的代表性路线合成。
C43H75D4NO2,Ms m/z:[M+H+]646.7;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.41(t,2H),2.26-2.15(m,10H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H).
实施例16:
化合物16的合成
化合物16可根据实施例1描述的代表性路线合成。
C43H75D4NO2,Ms m/z:[M+H+]646.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.43(t,1H),2.26-2.14(m,11H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H).
实施例17:
化合物17的合成
分子量:647.14
化合物17可根据实施例1描述的代表性路线合成。
C43H74D5NO2,Ms m/z:[M+H+]647.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.41(t,2H),2.26-2.14(m,10H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H)。
实施例18:
化合物18的合成
分子量:647.14
化合物18可根据实施例1描述的代表性路线合成。
C43H74D5NO2,Ms m/z:[M+H+]647.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.43(t,1H),2.26-2.14(m,10H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H)。
实施例19:
化合物19的合成
分子量:647.14
化合物19可根据实施例1描述的代表性路线合成。
C43H74D5NO2,Ms m/z:[M+H+]647.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.41(t,2H),2.26-2.15(m,9H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H)。
实施例20:
化合物20的合成
分子量:647.14
化合物20可根据实施例1描述的代表性路线合成。
C43H74D5NO2,Ms m/z:[M+H+]647.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.43(t,1H),2.26-2.14(m,10H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H)。
实施例21:
化学式:C43H74D5NO2
分子量:647.14
化合物21可根据实施例1描述的代表性路线合成。
C43H74D5NO2,Ms m/z:[M+H+]647.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.43(t,1H),2.26-2.14(m,10H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H)。
实施例22:
化合物21的合成
化合物17可根据实施例1描述的代表性路线合成。
C43H74D5NO2,Ms m/z:[M+H+]647.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.43(t,1H),2.26-2.14(m,10H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H)。
实施例23:
化合物23的合成
分子量:648.14
化合物23可根据实施例1描述的代表性路线合成。
C43H73D6NO2,Ms m/z:[M+H+]648.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.26-2.14(m,10H),1.51-1.50(m,6H),1.33-1.26(m,36H),0.88(t, 6H)。
实施例24:
化合物24的合成
分子量:648.14
化合物24可根据实施例1描述的代表性路线合成。
C43H73D6NO2,Ms m/z:[M+H+]648.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.26-2.14(m,10H),1.51-1.50(m,6H),1.33-1.26(m,36H),0.88(t, 6H)。
实施例25:
化学式:C43H73D6NO2
分子量:648.14
化合物25可根据实施例1描述的代表性路线合成。
C43H73D6NO2,Ms m/z:[M+H+]648.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.43(t,1H),2.26-2.14(m,9H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H)。
实施例26:
化合物26的合成
分子量:648.14
化合物26可根据实施例1描述的代表性路线合成。
C43H73D6NO2,Ms m/z:[M+H+]648.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.44-2.42(t,2H),2.26-2.15(m,8H),1.51-1.50(m,6H),1.33-1.26(m, 36H),0.88(t,6H)。
实施例27:
化合物27的合成
分子量:649.14
化合物25可根据实施例1描述的代表性路线合成。
C43H72D7NO2,Ms m/z:[M+H+]649.7;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82-2.78(d,4H),2.26-2.14(m,9H),1.51-1.50(m,6H),1.33-1.26(m,36H),0.88(t,6H)。
实施例28:
化合物28的合成
分子量:649.15
化合物29可根据实施例1描述的代表性路线合成。
C43H72D7NO2,Ms m/z:[M+H+]649.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82~2.78(d,4H),2.43(s,1H),2.26-2.15(m,8H),1.51-1.50(m,6H),1.33-1.26(m,36H), 0.88(t,6H).
实施例29:
化合物29的合成
分子量:650.16
化合物29可根据实施例1描述的代表性路线合成。
C43H71D8NO2,Ms m/z:[M+H+]650.6;1H-NMR(300MHz):δ5.4-5.27(m,8H),3.89-3.82(m,3H),2.82~2.80(d,4H),2.26(m,8H),1.51-1.50(m,6H),1.33-1.26(m,36H),0.88(t,6H).
实施例30
利用脂质纳米颗粒组合物的荧光素酶mRNA体内评价
将阳离子脂质、DSPC、胆固醇和PEG-脂质以50:10:38:2或48:10:40:2的摩尔比溶解在乙醇中。以约10:1至30:1的总脂质与mRNA的重量比制备脂质纳米颗粒(LNP)。简而言之,将mRNA在10mL至50mL柠檬酸盐缓冲液(pH=4.0)稀释至0.15mg/mL。使用注射器泵,将脂质的乙醇溶液与mRNA水溶液以约1:5至1:3(体积/体积)的比例混合,总流速为10 mL/min以上。然后去除乙醇,并通过透析用PBS替代外部的缓冲液。最后,将脂质纳米颗粒通过0.2μm孔径的无菌过滤器过滤。使用Malvern Zetasizer Nano ZS通过准弹性光散射测定的脂质纳米颗粒的粒径为直径大约65-105nm,并且在一些情况下,直径大约75-100nm。
根据国家科学技术委员会制定的指南,在6-8周龄的雌性C57BL/6小鼠,8-10周龄CD-1 小鼠上进行研究。通过尾静脉注射全身性给予不同剂量的mRNA脂质纳米颗粒,并在给药后的特定时间点(例如5小时)使动物安乐死。将肝脏和脾脏收集在预先称重的管中,确定重量,立即在液氮中快速冷冻,并且在-80℃下储存,直至用于分析。
对于肝脏,切割约50mg以便在2mL FastPrep管(MP Biomedicals,Solon OH)中进行分析。向各个管中加入1/4"陶瓷球(MP Biomedicals),并将平衡至室温的500μL的Glo裂解缓冲液-GLB(Promega,Madison WI)加入到肝脏组织中。使用FastPrep24仪器(MPBiomedicals) 将肝脏组织在2×6.0m/s下均匀化15秒。将匀浆在室温下孵育5分钟,然后在GLB中进行1:4稀释,并使用SteadyGlo荧光素酶测定系统(Promega)进行评估。具体地,将50μL的稀释的组织匀浆与50μL的SteadyGlo底物反应,摇振10秒,接着孵育5分钟,然后使用SpectraMAX_L化学发光型酶标仪(美谷分子仪器(上海)有限公司)定量。通过使用BCA蛋白质定量试剂盒(上海易色医疗科技有限公司)来确定测定的蛋白质的量。然后将相对发光度单位(RLU)归一化成所测定蛋白质的总μg。为了将RLU转化成μg荧光素酶,用QuantiL μM重组荧光素酶(Promega)生成了标准曲线。
来自Trilink Biotechnologies的FLuc mRNA(L-6107)将表达荧光素酶蛋白,其最初从萤火虫(pHotinus pyralis)中分离出来。Fluc通常用于哺乳动物细胞培养物中以测量基因表达和细胞活力。其在底物萤光素存在下发射出生物性光。这种加帽并且聚腺昔酸化的mRNA被5-甲基胞苷和假尿苷完全取代。
实施例31
所配制得脂质的pKa的测定
所配制的阳离子脂质的pKa与用于递送核酸的LNP的效果相关。优选的pKa范围是5~7。使用基于2-(对甲苯胺基)-6-荼磺酸(TNS)的荧光的分析,在脂质纳米颗粒中测定各阳离子脂质的pKa。如实施例27中所述,使用有序的方法来制备在PBS中的浓度为0.4mM总脂质的包含阳离子脂质/DSPC/胆固醇/PEG脂质(50/10/38/2mol%)的脂质纳米颗粒。将TNS在蒸馏水中制备成100μM储备溶液。将囊泡稀释成在2mL缓冲溶液中含24μM脂质,所述缓冲溶液含有10mM HEPES、10mM MES、10mM乙酸按、130mM NaCl,其中pH值为 2.5~11.0。加入等份的TNS溶液以产生lμM的终浓度,并且在涡旋混合之后,在室温下使用 321nm和445nm的激发波长和发射波长在SLM Aminco Series 2发光分光光度计中测量荧光强度。对荧光数据应用S形最佳拟合分析,并将pKa测量为产生半数最大荧光强度的pH。
实施例32
使用体内荧光素酶mRNA表达的啮齿动物模型测定含有各种阳离子脂质的脂质纳米颗粒制剂的效能
为了比较的目的,如实施例30所述,使用有序混合方法,将这些脂质也用于配制含有 FLuc mRNA(L-6107)的脂质纳米颗粒。使用以下摩尔比来配制脂质纳米颗粒:50%阳离子脂质/10%二硬脂酰磷脂酰胆碱(DSPC)/38%胆固醇/2%PEG脂质("PEG-DMG",即,(1-(单甲氧基一聚乙二醇)-2,3一二肉豆蔻酰基甘油,平均PEG分子量为2000)。如实施例30所述,在经由尾静脉注射施用之后的5小时,通过测量肝脏中的荧光素酶表达来确定相对活性。在0.3和1.0mg mRNA/kg的剂量下比较所述活性,并表达成在如实施例30所述的施用之后5 小时测量的ng荧光素酶/g肝脏。实施例31及32结果如表2所示。
表2与mRNA表现出活性的比较脂质
以上所述实施例的各技术特征可以进行任意的组合,为使描述简洁,未对上述实施例中的各个技术特征所有可能的组合都进行描述,然而,只要这些技术特征的组合不存在矛盾,都应当认为是本说明书记载的范围。
以上所述实施例仅表达了本发明的几种实施方式,其描述较为具体和详细,但并不能因此而理解为对公开专利范围的限制。应当指出的是,对于本领域的普通技术人员来说,在不脱离本发明构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。因此,本发明专利的保护范围应以所附权利要求为准。
Claims (15)
2.选自表1中的化合物的化合物。
3.包含权利要求1~2中任一项所述的化合物和治疗剂和/或预防剂的组合物。
4.如权利要求3所述的组合物,其还包含选自中性脂质、类固醇以及聚合物缀合的脂质中的一种或多种赋形剂。
5.如前述权利要求4所述的组合物,其中所述组分中的中性脂质选自以下的一种或多种物质混合:1,2-二硬脂酰基-sn-甘油-3-磷酸胆碱(DSPC)、1,2-二棕榈酰基-sn-甘油-3-磷酸胆碱(DPPC)、1,2-二肉豆寇基-sn-甘油-磷酸胆碱(DMPC)、1,2-二油酰基-sn-甘油-3-磷酸胆碱(DOPC)、1-棕榈酰基-2-油酰基-sn-甘油-3-磷酸胆碱(POPC)、1,2-二油酰基-sn-甘油-3-磷酸乙醇胺(DOPE)和鞘磷脂(SM)。
6.如前述权利要求5所述的组合物,其中所述中性脂质为DSPC。
7.如前述权利要求4~6所述的组合物,其中所述组分中的类固醇选自以下一种或多种物质混合:胆固醇、粪固醇、谷固醇、麦角固醇、菜油固醇、豆固醇、菜籽固醇、番茄碱、熊果酸、α-生育酚。
8.如前述权利要求7所述的组合物,其中所述类固醇为胆固醇。
9.如前述权利要求4~8所述的组合物,其中所述组分中的聚合物缀合的脂质为聚乙二醇化脂质。
10.如前述权利要求中9所述的组合物,其中所述聚乙二醇化脂质为1,2-二肉豆蔻酰基-sn-甘油甲氧基聚乙二醇(PEG-DMG)。
11.如前述权利要求中任一项所述的组合物,其中所述治疗剂和/或预防剂是能够引起免疫响应的疫苗或化合物,其中包括核酸。
12.如前述权利要求11的组合物,其中所述核酸为RNA,其选自以下组成:siRNA、aiRNA、miRNA、dsRNA、shRNA、mRNA以及其混合物。
13.如前述权利要求12的组合物,其中所述RNA为mRNA。
14.向有需要的受试者施用治疗剂和/或预防剂的方法,所述方法包括制备或提供上述权利要求中任一项所述的组合物,并向所述对象施用所述组合物。
15.如前述权利要求中任一项所述的受试者为哺乳动物或人。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111030769.4A CN115745941A (zh) | 2021-09-03 | 2021-09-03 | 新型阳离子脂质化合物 |
PCT/CN2022/092599 WO2023029578A1 (zh) | 2021-09-03 | 2022-05-13 | 新型阳离子脂质化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111030769.4A CN115745941A (zh) | 2021-09-03 | 2021-09-03 | 新型阳离子脂质化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115745941A true CN115745941A (zh) | 2023-03-07 |
Family
ID=85332896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111030769.4A Pending CN115745941A (zh) | 2021-09-03 | 2021-09-03 | 新型阳离子脂质化合物 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115745941A (zh) |
WO (1) | WO2023029578A1 (zh) |
-
2021
- 2021-09-03 CN CN202111030769.4A patent/CN115745941A/zh active Pending
-
2022
- 2022-05-13 WO PCT/CN2022/092599 patent/WO2023029578A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
WO2023029578A1 (zh) | 2023-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7585519B2 (en) | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | |
JP2022549253A (ja) | 治療薬の細胞内送達のためのカーボネート含有脂質化合物及び組成物 | |
CN103857654A (zh) | 用于定向药物输送和增强siRNA活性的化合物 | |
WO2023186149A1 (zh) | 一种脂质化合物、包含其的组合物及应用 | |
WO2023024513A1 (zh) | 新型阳离子脂质化合物 | |
WO2023015904A1 (zh) | 一种新型阳离子脂质化合物 | |
CN115745942A (zh) | 新型阳离子脂质化合物 | |
CN115724806A (zh) | 新型阳离子脂质化合物(二) | |
CN115745941A (zh) | 新型阳离子脂质化合物 | |
CN115710193A (zh) | 新型阳离子脂质化合物 | |
CN115772089A (zh) | 新型阳离子脂质化合物 | |
CN115703714A (zh) | 新型阳离子脂质化合物 | |
CN115745815A (zh) | 新型阳离子脂质化合物 | |
CN115745819A (zh) | 新型阳离子脂质化合物 | |
CN115710191A (zh) | 新型阳离子脂质化合物 | |
CN115710196A (zh) | 新型阳离子脂质化合物(一) | |
CN115894281A (zh) | 新型阳离子脂质化合物、其制备方法、组合物及应用 | |
CN115925604A (zh) | 吡咯烷类新型脂质化合物、其制备方法、组合物及应用 | |
JP7419542B2 (ja) | 脂質化合物及びその組成物 | |
CN115850686A (zh) | 新型氘代peg脂质化合物、其制备方法、组合物和应用 | |
AU2007214359B2 (en) | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | |
CN118178664A (zh) | 一种用于核酸递送的脂质材料及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination |